Bristol Myers Squibb (BMS; NYSE: BMY) has unveiled results from several Phase III trials for its S1P receptor modulator Zeposia (ozanimod) in the treatment of relapsing forms of multiple sclerosis (MS). In a long-term study, the oral medication demonstrated a low annualized relapse rate, with disability progression observed in only 17.2% and 15.2% of participants after 3 and 6 months, respectively.
In another trial, permanent discontinuation of Zeposia was followed by a relapse in 2.2% of cases, typically occurring within 90 days of stopping treatment. However, the majority of these relapses were mild or moderate in severity, and patients subsequently experienced complete recovery, indicating no post-treatment rebound effect.
Furthermore, the long-term safety profile of Zeposia was found to be consistent with previous observations.- Flcube.com
